Generic drugmakers have pledged to work with the FDA to formalize the process for manufacturers and other members of the supply chain to report drug shortages to the FDA, "as many now do voluntarily," says a statement from the Generic Pharmaceutical Association (GPhA). Ralph Neas, CEO, adds that "dramatically reducing drug shortages is not out of reach." Several drugmakers, including Teva ($TEVA) and Hospira ($HSP), deferred to GPhA when asked for comment regarding Monday's executive order and the U.S. Department of Health and Human Services report on the economic causes of shortages. Report